Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARINET: Lanreotide in GEP-NETs
NCT00353496Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jun 2006
- Primary completion
- Apr 2013
- Modality
- Peptides
- Countries
- 15
01
Overview
A Phase 3 trial of lanreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), sponsored by Ipsen. Started Jun 2006; status: completed.
02
Drugs
lanreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Beyond the preview
Go deeper on NCT00353496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00353496.